- Home
- DXR vs ACRV Comparison
DXR vs ACRV Comparison
Compare DXR & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- ACRV
- Stock Information
- Founded
- DXR 1970
- ACRV 2018
- Country
- DXR United States
- ACRV United States
- Employees
- DXR N/A
- ACRV N/A
- Industry
- DXR Medical/Dental Instruments
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- DXR Health Care
- ACRV Health Care
- Exchange
- DXR Nasdaq
- ACRV Nasdaq
- Market Cap
- DXR 40.3M
- ACRV 42.5M
- IPO Year
- DXR N/A
- ACRV 2022
- Fundamental
- Price
- DXR $7.77
- ACRV $1.93
- Analyst Decision
- DXR Strong Buy
- ACRV Strong Buy
- Analyst Count
- DXR 1
- ACRV 6
- Target Price
- DXR $25.00
- ACRV $21.80
- AVG Volume (30 Days)
- DXR 5.2K
- ACRV 441.2K
- Earning Date
- DXR 01-01-0001
- ACRV 05-13-2025
- Dividend Yield
- DXR N/A
- ACRV N/A
- EPS Growth
- DXR 86.16
- ACRV N/A
- EPS
- DXR 0.11
- ACRV N/A
- Revenue
- DXR $119,714.00
- ACRV N/A
- Revenue This Year
- DXR N/A
- ACRV N/A
- Revenue Next Year
- DXR N/A
- ACRV N/A
- P/E Ratio
- DXR $71.76
- ACRV N/A
- Revenue Growth
- DXR N/A
- ACRV N/A
- 52 Week Low
- DXR $6.55
- ACRV $1.30
- 52 Week High
- DXR $10.00
- ACRV $10.29
- Technical
- Relative Strength Index (RSI)
- DXR 49.33
- ACRV 37.28
- Support Level
- DXR $7.35
- ACRV $1.66
- Resistance Level
- DXR $7.98
- ACRV $2.12
- Average True Range (ATR)
- DXR 0.43
- ACRV 0.29
- MACD
- DXR -0.00
- ACRV 0.16
- Stochastic Oscillator
- DXR 52.94
- ACRV 67.42
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.